Pediatric Venous Thromboembolism (VTE): An Appraisal of Predictive Risk Factors, Prevention and Treatment

November 29, 2022

The BloodNet Education Conference Series is an educational event offered periodically throughout 2022. Each session will explore specialized topics in the field of hematology, featuring talks and discussions from leading pediatric critical care, transfusion medicine and hematology experts. 

Target Audience

The target audience for this series includes physicians, fellows and healthcare providers who have an interest in pediatric critical care and hematology. 

Learning Objectives

At the conclusion of this educational activity, participants should be able to:

  • Evaluate biomarkers and other predictive risk factors for venous thromboembolic events. 
  • Discuss the evidence and strategies for the prevention of hospital-acquired VTE. 
  • Discuss past and present treatment modalities for pediatric VTE. 
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Attendance
Course opens: 
09/26/2022
Course expires: 
12/13/2022
Event starts: 
11/29/2022 - 1:00pm MST
Event ends: 
11/29/2022 - 3:00pm MST
Cost:
$0.00
Rating: 
0

Faculty

 

Julie Jaffray, MD
Assistant Professor of Pediatrics
Division of Pediatric Hematology and Oncology
University of California - San Diego
Rady Children's Hospital

Vince Faustino, MD, MHS
Professor of Pediatrics
Section of Critical Care
Yale School of Medicine
Visiting Professor of Pediatrics
University of the Philippines
College of Medicine

Leslie Raffini, MD, MSCE
Professor of Pediatrics
Division of Pediatric Hematology and Oncology
Medical Director, Hemostasis and Thrombosis Center
Children's Hospital of Philadelphia
University of Pennsylvania

Planning Committee

 

Michele Loi, MD, Vince Faustino, MD, Alison Nair, MD


Disclosures

 

Vincent S. Faustino, MD, speaker for this activity, is an advisory board member for Boehringer Ingelheim and Dexcom. 

Julie Jaffray, MD, speaker for this activity, is a consultant for Bayer, Genetech and Octapharma. 

Leslie Raffini, MD, MSCE, speaker for this activity, is on the advisory board for Janssen, Genentech and Boehringer Ingelheim and owns stock in Amgen and Blue.

 

Planners, faculty, and others in control of content (either individually or as a group) have no relevant financial relationships with ineligible companies.

All of the relevant financial relationships listed have been mitigated.

Children’s Hospital Colorado is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Children’s Hospital Colorado designates this Other (Internet live) activity for a maximum of 2.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Attendance

Price

Cost:
$0.00
Please login or register to take this course.